Read more

October 11, 2022
1 min read
Save

Hydroquinone-free serum efficacious in hyperpigmentation treatment

DENVER — A novel hydroquinone-free correcting serum proved efficacious and tolerable in women with hyperpigmentation, according to a study presented here.

“Hyperpigmentation is often characterized by uneven skin tone and a photoaged appearance and ultimately arises from excess melanin disposition,” Elizabeth T. Makino, BS, CCRA, MBA, director of clinical development skincare at AbbVie, said during a video abstract presentation at the American Society for Dermatologic Surgery Annual Meeting. “The objective for this study was to assess the efficacy and tolerability of a novel hydroquinone-free, multimodal, pigment-correcting serum, which I will refer to as LYT3, compared to the 4% [hydroquinone (HQ)], which is a prescription topical gold standard.”

DERM1022ASDS_Makino_Graphic_01
A novel hydroquinone-free correcting serum proves efficacious and tolerable in women with hyperpigmentation.

Women aged 30 to 65 years with moderate to severe hyperpigmentation on both sides of the face were included in the split-face, double-blind, randomized controlled study. A minimum of 25 patients for each skin type were placed into subgroups including African American, Hispanic white, Asian, and non-Hispanic white with an additional subgroup for melasma. Each received a twice-daily application of the correcting serum LYT3 on a randomly assigned facial side and 4% HQ on the opposite side for 12 weeks.

Clinical assessments were taken at baseline and at weeks 2, 4, 8 and 12.

Results were similar across all race and ethnicity subgroups. Patients saw an approximate 12% improvement in overall hyperpigmentation and an approximate 8% improvement in skin tone evenness with both LYT3 and 4% HQ treatments.

Although there were no significant differences between the results, participants consistently preferred LYT3 to 4% HQ at every visit, with 57 participants preferring LYT3 while 43 preferring 4% HQ at week 12. The melasma subgroup also reported a significantly higher satisfaction with LYT3 compared with 4% HQ (63 vs. 37).

“LYT3 significantly improved facial hyperpigmentation, including melasma, across multiple race and ethnicity subgroups and was well tolerated,” Makino said.